The historical rank and industry rank for Joinn Laboratories (China) Co's Net Cash per Share or its related term are showing as below:
SHSE:603127'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 7.57 Med: 17.83 Max: 184.37
Current: 7.57
During the past 12 years, the highest Price-to-Net-Cash Ratio of Joinn Laboratories (China) Co was 184.37. The lowest was 7.57. And the median was 17.83.
SHSE:603127's Price-to-Net-Cash is ranked worse than 52.86% of 70
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.785
vs SHSE:603127: 7.57
Joinn Laboratories (China) Co Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Joinn Laboratories (China) Co Net Cash per Share Chart
Competitive Comparison of Joinn Laboratories (China) Co's Net Cash per Share
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co's Price-to-Net-Cash Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's Price-to-Net-Cash falls into.
Joinn Laboratories (China) Co Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co (SHSE:603127) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Joinn Laboratories (China) Co Net Cash per Share Related Terms
Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Joinn Laboratories (China) Co (SHSE:603127) Business Description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHSE:603127 has been successfully added to your 